[A15-34] Pertuzumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)

Last updated 01.12.2015

Project no.:

Commission awarded on 20.08.2015 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:


After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


Neoadjuvant use of pertuzumab in HER2-positive breast cancer: hint of lesser benefit

No proof of positive effects / more treatment discontinuations due to side effects

Federal Joint Committee (G-BA)

2016-02-18 G-BA decision was published.

G-BA documents on this decision


Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.